Don’t be a basic witch this year for Halloween because honestly you deserve better and no one wants to see you in a taco foam costume for the third year in a row. Transform into the “Hi, welcome to Chili’s” vine with our first-ever Halloween costume. Go to welcometochilis.com to get your hands on this Halloween treat while supplies last.
This one-of-a-kind Chili’s® Grill & Bar costume is sourced from tears of pure laughter, made with the finest cotton-polyester blend known to man and designed with a custom pattern you won’t find anywhere else. This Halloween, slip on your boxers and hold up that cardboard cell and get ready to welcome people to Chili’s all night long!
To view the multimedia release go to:
https://www.multivu.com/players/English/8246359-chilis-halloween-costume-of-2018/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
SunPower (NASDAQ:SPWR) has once again raised the bar by introducing the highest-power solar panels available today for the residential market. In the United States, the company has launched its Next Generation Technology home solar panel called A-Series, delivering 400 and 415 watts of power. In Europe and Australia, homeowners can also now order a 400-watt solar panel from SunPower called Maxeon® 3. Each is the first home solar panel to deliver more than 400 watts in its region and is designed to deliver 60 percent more energy in the same amount of roof space over the first 25 years compared to conventional solar.
“SunPower is introducing the world’s first 400-watt residential solar panels as most in the industry are just crossing the 300-watt threshold for home solar,” said Jeff Waters, CEO of the SunPower Technologies business unit. “Our record-breaking cell technology and innovative research and development efforts have enabled us to fit more power capacity on rooftops than we ever have before. Our growing panel portfolio is delivering unprecedented value across global markets that goes unmatched by any other residential solar technology currently available.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8252054-sunpower-a-series-next-gen-solar-panels/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
House of Napius is India's first line of radiation safe maternity wear using path breaking NESA technology (Non-Ionizing Electromagnetic Shielding Alternatives.
Most expectant mothers understand that carrying a child means taking extra safety measures to protect the growing life. Mothers-to-be are aware that they need to avoid certain chemicals, foods, and some beverages. Our line of radiation safe maternity wear provides an additional safeguard by shielding against radiation from cell phones, wireless routers, laptop and computers. House of Napius offers a wide range of revolutionary, radiation safe Maternity wear for the first time in India.
With a lack of choice and growing radiation concerns Founder Director, Nehal Mehta says: “Today we cannot live a gadget or appliance free lifestyle. At House of Napius, we have created a solution to block the radiation from these gadgets which are used on a daily basis such as cellphones, microwaves, laptops, scanners and ipads. We are launching our first product category of maternity wear and will be expanding into other categories such a kidswear, womenswear and menswear in the future.”
When it comes to dressing during pregnancy, comfort and style are key factors/aspects. The new range of maternity wear by House of Napius includes office wear, day wear, resort, night wear and cocktail dresses. Each garment is designed to not only protect the child, but provide unparalleled comfort and ease of use for the pregnant mother. House of Napius maternity wear is available in a multitude of colours’ and patterns and will keep your child protected all through those precious nine months.
To view the Multimedia release go to:
http://www.multivu.com/players/English/7595451-house-napius-maternity-wear-india/
We\'re Hub Innovations, a consumer products company born with the mission of developing unique, innovative products that enhance the user\'s experience with their mobile devices. Design, functionality and simplicity is what we live by.
From cell phones to tablets and everything in between, Hub Innovations is focused on developing solutions to help consumers run their personal and professional lives more efficiently. From running a fast-growing national distributor of high quality agrochemicals to pioneering nation-wide retail vaccination programs.
Olives from Spain offers American consumers great recipes with this millenary ingredient from the Mediterranean, during their Have an Olive Day campaign. Ideal in high temperature weather, olives are a key component of the Mediterranean Diet which is part of the Intangible Cultural Heritage of Humanity. The supply of olives - is extensive with numerous formats and more than eighty types of fillings.
The versatility of European olives means they can be used in any recipe as they combine four classic flavours; sour, bitter, sweet and savoury. The antioxidants maintain cell integrity furthermore; olives are a natural source of antioxidant Vitamin E.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8368151-olives-from-spain-new-recipes-for-summer/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Olives from Spain offers American consumers great recipes with this millenary ingredient from the Mediterranean, during their Have an Olive Day campaign. Ideal in high temperature weather, olives are a key component of the Mediterranean Diet which is part of the Intangible Cultural Heritage of Humanity. The supply of olives - is extensive with numerous formats and more than eighty types of fillings.
The versatility of European olives means they can be used in any recipe as they combine four classic flavours; sour, bitter, sweet and savoury. The antioxidants maintain cell integrity furthermore; olives are a natural source of antioxidant Vitamin E.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8368151-olives-from-spain-new-recipes-for-summer/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
